Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Language
Publication year range
1.
Int J Biol Macromol ; 259(Pt 2): 129250, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38199551

ABSTRACT

This study delves into the potential of chito-oligosaccharides (COS) to promote osteoblast differentiation and prevent osteoporosis, utilizing experiments with mouse MSCs and the zebrafish model. The preliminary biocompatibility study affirms the non-toxic nature of COS across various concentrations. In the osteoblast differentiation study, COS enhances ALP activity and calcium deposition at the cellular level. Moreover, COS induces the upregulation of molecular markers, including Runx2, Type I collagen, ALP, osteocalcin, and osteonectin in mouse MSCs. Zebrafish studies further demonstrate COS's anti-osteoporotic effects, showcasing its ability to expedite fin fracture repair, vertebral mineralization, and bone mineralization in dexamethasone-induced osteoporosis models. The scale regenerative study reveals that COS mitigates the detrimental effects of dexamethasone induced osteoclastic activity, reducing TRAP and hydroxyproline levels while elevating the expression of Runx2a MASNA isoform, collagen2α, OC, and ON mRNAs. Additionally, COS enhances calcium and phosphorus levels in regenerated scales, impacting the bone-healthy calcium-to­phosphorus ratio. The study also suggests that COS modulates the MMP3-Osteopontin-MAPK signaling pathway. Overall, this comprehensive investigation underscores the potential of COS to prevent and treat osteoporosis. Its multifaceted cellular and molecular effects, combined with in vivo bone regeneration and repair, propose that COS may be effective in addressing osteoporosis and related bone disorders. Nonetheless, further research is imperative to unravel underlying mechanisms and optimize clinical applications.


Subject(s)
Chitosan , Osteoporosis , Mice , Animals , Zebrafish/metabolism , Chitosan/metabolism , Calcium/metabolism , Osteogenesis , Osteoporosis/metabolism , Cell Differentiation , Dexamethasone/pharmacology , Osteoblasts , Phosphorus/metabolism
2.
Biomed Pharmacother ; 105: 440-448, 2018 Sep.
Article in English | MEDLINE | ID: mdl-29879628

ABSTRACT

During the last few decades, gold nanoparticles (AuNP's) have gained considerable attention in nanomedicine and expanded its application in clinical diagnosis and as therapeutics. Employing plant extract for synthesising gold nanoparticles proves to be an eco-friendly technology for large scale production. It is highly economical and suitable for biological applications by negating the use of chemicals involved in conventional route. In this study, AuNP's was prepared by a simple one step method of employing aqueous Mangifera indica seed extract as a reducing agent. Scanning electron microscopy and transmission electron microscopy revealed spherical shaped nanoparticles and dynamic light scattering analysis indicated the AuNP's to be approximately 46.8 nm in size. AuNP's efficiently inhibited the growth of E. coli and S. aureus by its inherent ability to generate reactive oxygen species (ROS) and exhibited detrimental effects towards the tested bacterial species. Biocompatibility assessment indicated the non-toxic nature of AuNP's towards mesenchymal stem cells at 25 µg/ml and interestingly, suppressed the growth of human gastric cancer cells under in vitro culture conditions. AuNP's significantly exhibited anti-angiogenic property in chick chorioallantoic membrane model (CAM) by downregulating Ang-1/Tie2 pathway. Overall, the synthesized AuNP's exhibited antibacterial and anti-angiogenic properties with high biocompatibility thereby supporting its candidature for various biomedical applications. It can be employed in suppressing tumor growth, combat inflammatory diseases that necessitate the involvement of angiogenesis suppression, and antibacterial activity is suitable for its clinical translation to negate surgery associated infections.


Subject(s)
Angiogenesis Inhibitors/therapeutic use , Anti-Bacterial Agents/therapeutic use , Antineoplastic Agents/therapeutic use , Biocompatible Materials/chemistry , Gold/chemistry , Mangifera/chemistry , Metal Nanoparticles/chemistry , Plant Extracts/therapeutic use , Angiogenesis Inhibitors/pharmacology , Angiopoietin-1/metabolism , Animals , Anti-Bacterial Agents/pharmacology , Antineoplastic Agents/pharmacology , Cell Line, Tumor , Cell Proliferation/drug effects , Chickens , Chorioallantoic Membrane/drug effects , Chorioallantoic Membrane/metabolism , Down-Regulation/drug effects , Escherichia coli/drug effects , Humans , Metal Nanoparticles/ultrastructure , Microbial Sensitivity Tests , Neovascularization, Physiologic/drug effects , Plant Extracts/pharmacology , Receptor, TIE-2/metabolism , Seeds/chemistry , Spectrophotometry, Ultraviolet , Staphylococcus aureus/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL